IP Library Granted Patent US 11,395,834
Granted Patent B2
US 11,395,834 · App. 16/823,150 · Granted Jul 26, 2022

Bioavailable polyamines

Inventor: Mark R Burns (Epsom, NH)
Assignee: Aminex Therapeutics, Inc.
A61K31/785A61K9/2054A61K9/2846A61K9/2886A61K45/06A61P35/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,395,834
App. No.
16/823,150
Granted
Jul 26, 2022
Kind
B2
Abstract

Disclosed herein are pharmaceutical salts of a cationic protonated polyamine pharmaceutical agent and an anionic organic carboxylate which is hydrophobic when in protonated form, particularly suited for oral administration, where these salts have good bioavailability in solid dosage forms and may be used in the treatment of cancer and other medical conditions for which the pharmaceutical agent is intended.

Claims (17)

1. A method of treating a solid tumor cancer, comprising administering to a subject in need thereof a therapeutically effective amount of a salt of formula AMXT 1501:(capric acid) 2 , wherein AMXT 1501 has formula:

wherein the salt is administered in conjunction with difluoromethylornithine (DFMO), or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 , wherein the salt is administered in a solid dosage form to the subject.

3. The method of claim 1 , wherein the salt has chemical structure:

4. The method of claim 1 , comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising the salt of formula AMXT 1501:(capric acid) 2 and a pharmaceutically acceptable inert component.

5. The method of claim 4 , wherein the pharmaceutical composition is in a solid oral dosage form.

6. The method of claim 5 , wherein the solid oral dosage form is enterically coated.

7. The method of claim 1 , further comprising administering DFMO, or a pharmaceutically acceptable salt thereof, to the subject.

8. The method of claim 1 , wherein the subject is a human.

9. The method of claim 1 , wherein from about 0.05 to 100 mg/kg per day of the salt is administered to the subject.

10. The method of claim 9 , wherein from about 5 to 50 mg/kg per day of the salt is administered to the subject.

11. The method of claim 1 , wherein the salt is administered to the subject once or twice per day.

12. The method of claim 1 , wherein the solid tumor cancer is breast cancer, prostate cancer, colon cancer or lung cancer.

13. The method of claim 1 , wherein the solid tumor cancer is breast cancer or colon cancer.

14. The method of claim 1 , wherein the solid tumor cancer is neuroblastoma, pancreatic cancer, bladder cancer, melanoma, skin cancer, kidney cancer, head and neck cancer, ovarian cancer or thyroid cancer.

15. The method of claim 1 , wherein the solid tumor cancer is neuroblastoma, pancreatic cancer, melanoma, skin cancer or head and neck cancer.

16. The method of claim 1 , wherein the solid tumor cancer is glioblastoma.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 23, 2022
From: BURNS, MARK R.
To: AMINEX THERAPEUTICS INC.
Reel/Frame 059374/0774 →
Continuity (3)
Continuation 15753291
Provisional Application 62313657 · Mar 25, 2016
Related Publication 20200352983A1 · Nov 12, 2020
Cited By (1)
US 12,364,709